CA2874436A1 - Translocation of non-natural chemical entities through anthrax protective antigen pore - Google Patents

Translocation of non-natural chemical entities through anthrax protective antigen pore Download PDF

Info

Publication number
CA2874436A1
CA2874436A1 CA2874436A CA2874436A CA2874436A1 CA 2874436 A1 CA2874436 A1 CA 2874436A1 CA 2874436 A CA2874436 A CA 2874436A CA 2874436 A CA2874436 A CA 2874436A CA 2874436 A1 CA2874436 A1 CA 2874436A1
Authority
CA
Canada
Prior art keywords
protein
reagent
peptide
pore
lfn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2874436A
Other languages
English (en)
French (fr)
Inventor
Xiaoli LIAO
Amy E. Rabideau
Bradley L. Pentelute
Jingjing LING
Gizem Akcay
John Collier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Harvard University
Original Assignee
Massachusetts Institute of Technology
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology, Harvard University filed Critical Massachusetts Institute of Technology
Publication of CA2874436A1 publication Critical patent/CA2874436A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2874436A 2012-05-21 2013-05-21 Translocation of non-natural chemical entities through anthrax protective antigen pore Abandoned CA2874436A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261649421P 2012-05-21 2012-05-21
US201261649866P 2012-05-21 2012-05-21
US61/649,866 2012-05-21
US61/649,421 2012-05-21
PCT/US2013/042118 WO2013177231A1 (en) 2012-05-21 2013-05-21 Translocation of non-natural chemical entities through anthrax protective antigen pore

Publications (1)

Publication Number Publication Date
CA2874436A1 true CA2874436A1 (en) 2013-11-28

Family

ID=49624302

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2874436A Abandoned CA2874436A1 (en) 2012-05-21 2013-05-21 Translocation of non-natural chemical entities through anthrax protective antigen pore

Country Status (5)

Country Link
US (2) US9731029B2 (cg-RX-API-DMAC7.html)
EP (1) EP2852619A4 (cg-RX-API-DMAC7.html)
JP (1) JP2015519344A (cg-RX-API-DMAC7.html)
CA (1) CA2874436A1 (cg-RX-API-DMAC7.html)
WO (2) WO2013177231A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2890501T3 (es) 2009-03-02 2022-01-20 Massachusetts Inst Technology Métodos y productos para la creación de perfiles enzimáticos in vivo
EP3950704A1 (en) 2011-03-15 2022-02-09 Massachusetts Institute Of Technology Multiplexed detection with isotope-coded reporters
EP2920319B1 (en) 2012-11-16 2020-02-19 Poseida Therapeutics, Inc. Site-specific enzymes and methods of use
EP2777714A1 (en) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
ES2828985T3 (es) 2013-06-07 2021-05-28 Massachusetts Inst Technology Detección basada en la afinidad de biomarcadores sintéticos codificados por ligando
AU2015277180A1 (en) * 2014-06-17 2017-01-12 Poseida Therapeutics, Inc. A method for directing proteins to specific loci in the genome and uses thereof
WO2016096740A1 (en) 2014-12-17 2016-06-23 F. Hoffmann-La Roche Ag Activity assay for bond forming enzymes
CN107001446A (zh) 2014-12-17 2017-08-01 豪夫迈·罗氏有限公司 采用分选酶的单步骤双多肽缀合酶促一锅反应
ES2886599T3 (es) 2015-06-17 2021-12-20 Poseida Therapeutics Inc Composiciones y métodos para dirigir proteínas a loci específicos en el genoma
BR112018003782A2 (pt) 2015-08-27 2018-09-25 Ipsen Pharma Sas composições e métodos para o tratamento da dor
EP3353291B1 (en) 2015-09-25 2021-06-09 F. Hoffmann-La Roche AG Novel soluble sortase a
EP3353314A1 (en) 2015-09-25 2018-08-01 H. Hoffnabb-La Roche Ag Transamidation employing sortase a in deep eutectic solvents
JP6895953B2 (ja) * 2015-09-25 2021-06-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ソルターゼａを利用してチオエステルを作製するための方法
WO2017177115A1 (en) 2016-04-08 2017-10-12 Massachusetts Institute Of Technology Methods to specifically profile protease activity at lymph nodes
EP3452407B1 (en) 2016-05-05 2024-04-03 Massachusetts Institute Of Technology Methods and uses for remotely triggered protease activity measurements
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
EP3607085A1 (en) 2017-04-07 2020-02-12 Massachusetts Institute Of Technology Methods to spatially profile protease activity in tissue and sections
CN108504670B (zh) * 2018-02-27 2022-01-04 温州医科大学 一种大肠杆菌冷休克助溶型表达质粒的构建方法及其应用
US11054428B2 (en) 2018-03-05 2021-07-06 Massachusetts Institute Of Technology Inhalable nanosensors with volatile reporters and uses thereof
EP3762404A4 (en) 2018-03-07 2022-05-11 Epicypher, Inc. ENGINEERING OF PEPTIDE LIGASE-MEDIATED RECOMBINANT NUCLEOSOMES
US20230133885A1 (en) * 2018-05-22 2023-05-04 The University Of Sydney New synthetic methods using native chemical ligation in flow
US12173349B2 (en) 2018-09-25 2024-12-24 Massachusetts Institute Of Technology Lung protease nanosensors and uses thereof
EP3911753A1 (en) 2019-01-17 2021-11-24 Massachusetts Institute of Technology Sensors for detecting and imaging of cancer metastasis
JP2025509645A (ja) * 2022-03-17 2025-04-11 オハイオ ステート イノベーション ファウンデーション 膜移行ドメイン及びその使用
JP2025515178A (ja) * 2022-05-04 2025-05-13 オハイオ・ステイト・イノベーション・ファウンデーション 植物細胞内への薬剤送達のための組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677274A (en) * 1993-02-12 1997-10-14 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Anthrax toxin fusion proteins and related methods
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US5770380A (en) 1996-09-13 1998-06-23 University Of Pittsburgh Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
WO1998056807A1 (en) 1997-06-13 1998-12-17 Gryphon Sciences Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution
GB0030038D0 (en) * 2000-12-08 2001-01-24 Univ Warwick Yeast-based assay
AU2003208502A1 (en) * 2002-03-05 2003-09-16 Fundacion Galileo Apoptogenic-bacteriocins combining broad spectrum antibiotic and selective anti-tumoral activities, and compositions and uses thereof
WO2005051976A2 (en) * 2003-11-20 2005-06-09 Ansata Therapeutics, Inc. Protein and peptide ligation processes and one-step purification processes
US7674881B2 (en) 2005-10-07 2010-03-09 The University Of Chicago Convergent synthesis of proteins by kinetically controlled ligation
WO2007083175A1 (en) * 2006-01-17 2007-07-26 West China Hospital, Sichuan University Antiviral bifunctional molecules, methods of construction and methods of treating virus-induced cancer therewith
US20130122043A1 (en) 2010-04-20 2013-05-16 Whitehead Institute For Biomedical Research Modified polypeptides and proteins and uses thereof
CA2824154A1 (en) 2011-01-10 2012-07-19 President And Fellows Of Harvard College Method for delivering agents into cells using bacterial toxins
WO2012142659A1 (en) 2011-04-19 2012-10-26 Baker Idi Heart And Diabetes Institute Holdings Limited Site-selective modification of proteins
EP2817341A4 (en) * 2012-02-23 2015-12-02 Harvard College MICROBIAL MODIFIED TOXIN RECEPTOR FOR THE DISTRIBUTION OF AGENTS IN CELLS

Also Published As

Publication number Publication date
EP2852619A1 (en) 2015-04-01
EP2852619A4 (en) 2016-04-27
WO2013177231A8 (en) 2014-01-16
WO2013177231A1 (en) 2013-11-28
JP2015519344A (ja) 2015-07-09
US20150165062A1 (en) 2015-06-18
US9731029B2 (en) 2017-08-15
US20150152134A1 (en) 2015-06-04
US9498538B2 (en) 2016-11-22
WO2013177221A1 (en) 2013-11-28

Similar Documents

Publication Publication Date Title
US9498538B2 (en) Translocation of non-natural chemical entities through anthrax protective antigen pore
Tsukiji et al. Sortase‐mediated ligation: a gift from gram‐positive bacteria to protein engineering
Cromm et al. Protease-resistant and cell-permeable double-stapled peptides targeting the Rab8a GTPase
US9303076B2 (en) Cell-penetrating peptides and uses thereof
US9188584B2 (en) Capture agents and related compositions, methods and systems
EP2474613B1 (en) Methods and compositions
ES2813867T3 (es) Biblioteca de péptidos y su uso
Meng et al. CXC-mediated cellular uptake of Miniproteins: forsaking “arginine magic”
Salim et al. Development of a cell-permeable cyclic peptidyl inhibitor against the Keap1–Nrf2 interaction
JP2016523088A (ja) ペプチドの細胞輸送をモニタリングする方法
WO2017070742A1 (en) Use of spycatcher as a protein scaffold for peptide display; and spycatcher/spytag cyclised peptides displayed on bacteriophage
US20120283136A1 (en) Compositions and methods for the rapid biosynthesis and in vivo screening of biologically relevant peptides
Crone et al. Modulation of coiled-coil binding strength and fusogenicity through peptide stapling
WO2015022504A2 (en) Peptide conjugates
Brown et al. Multiple synthetic routes to the mini-protein omomyc and coiled-coil domain truncations
Deuss et al. Parallel synthesis and splicing redirection activity of cell-penetrating peptide conjugate libraries of a PNA cargo
Ernst et al. The symmetric tetravalent sulfhydryl-specific linker NATBA facilitates a combinatorial “tool kit” strategy for phage display-based selection of functionalized bicyclic peptides
Chen et al. Macrocyclic Peptides Closed by a Thioether–Bipyridyl Unit That Grants Cell Membrane Permeability
US20170049906A1 (en) Translocation of non-natural chemical entities through anthrax protective antigen pore
Eldridge et al. Hydrazide reactive peptide tags for site-specific protein labeling
Gui et al. Discovering Cell‐Targeting Ligands and Cell‐Surface Receptors by Selection of DNA‐Encoded Chemical Libraries against Cancer Cells without Predefined Targets
Schissel et al. In-Cell Penetration Selection–Mass Spectrometry Produces Noncanonical Peptides for Antisense Delivery
Brown Macrocyclization Approaches Towards Stabilization of Secondary and Tertiary Protein Motifs: Synthetic Studies, Applications, and Uptake Studies
Hong Lim et al. Biotin‐assisted folding of streptavidin on the yeast surface
JP2017526379A (ja) シャガシンに基づく足場組成物、方法及び使用

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20190522